Health Claims on Mushroom Supplements: What's Legal and What's Not

Mushroom Supplement Regulation

3 tiers of claims

FDA law divides supplement health claims into three tiers with different evidence requirements. Most mushroom supplement marketing lives in the lowest tier, structure/function claims, which require FDA notification but not approval.

Bailey et al., Critical Reviews in Food Science and Nutrition, 2020

30 days

FDA notification required before a company can market structure/function claims on supplements

Required

the 'not evaluated by FDA' disclaimer is mandated by regulation, not optional brand language

14 years

of FDA warning letter analysis reveals disease claims as the most consistent labeling violation

Bailey et al., Critical Reviews in Food Science and Nutrition, 2020

View as image ↗

Every mushroom supplement label in the United States carries some version of the same disclaimer at the bottom: "These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." Most consumers read this as a legal formality or a hedge. It is actually a regulatory signal. The specific wording is not chosen by the company. It is mandated by federal regulation. Its presence indicates that the claims on the label are structure/function claims, the lowest evidence tier in the FDA's three-tier framework for supplement health language.

Understanding that framework helps make sense of what mushroom supplement advertising means and what it is prohibited from saying. This article is part of the broader guide to mushroom supplement regulation. For the FTC's parallel authority over advertising (as opposed to labeling), see FTC Enforcement Against Mushroom Supplement Companies.

The Three-Tier System: How FDA Law Divides Health Claims

Not all health claims work the same way under federal law. Bailey and colleagues' 2020 analysis of current regulatory guidelines laid out the framework that governs what dietary supplement companies, including mushroom supplement makers, can say about their products.^[1]

Tier 1: Structure/Function Claims. These claims describe how a nutrient or ingredient affects normal body structure or function. "Supports immune function," "maintains healthy brain activity," and "promotes energy production" are all structure/function claims. They describe normal physiological processes, not disease treatment or prevention. Companies can make these claims if they have substantiation on file (competent and reliable scientific evidence), notify the FDA within 30 days of first marketing the claim, and include the mandatory disclaimer on the label.

Tier 2: Authorized Health Claims. These claims describe a relationship between a food substance and a disease or health-related condition (for example, "calcium reduces the risk of osteoporosis"). They require the FDA to have reviewed and authorized the specific claim based on significant scientific agreement. Authorization takes time and evidence. Most dietary supplement claims do not go through this process. Mushroom supplement labels almost never make authorized health claims.

Tier 3: Disease Claims. These claims state that a supplement treats, prevents, cures, or reduces the risk of a disease. They are prohibited on dietary supplement labels without the product being classified as a drug and going through FDA drug approval. A supplement that claims to "treat cancer," "prevent diabetes," or "cure infection" is making a disease claim. That product is being marketed as a drug, which requires the full pharmaceutical approval process.

Most mushroom supplement marketing operates in Tier 1. The entire labeling and advertising compliance structure for mushroom companies is built around staying inside structure/function claim territory while not crossing into disease claim language that requires drug approval.

The three tiers of supplement health claims

How FDA Law Sorts a Health Claim — and Where Mushroom Supplements Fit

The same words about a mushroom supplement can be legal, require FDA pre-approval, or be outright prohibited depending on which tier they fall into. The evidence bar and the FDA's role change sharply across the three.

Structure/Function

Tier 1 — lowest bar

What it describes

Effect on normal body structure or function

Evidence bar

Substantiation on file (competent, reliable scientific evidence)

FDA review before marketing

None — 30-day notification only, no approval

Example claim

"Supports immune function"

Where mushroom supplements live

Almost all mushroom supplement labeling

Authorized Health Claim

Tier 2 — pre-approved

What it describes

Link between a substance and a disease/health condition

Evidence bar

Significant scientific agreement, reviewed by FDA

FDA review before marketing

Yes — FDA authorizes the specific claim first

Example claim

"Calcium reduces the risk of osteoporosis"

Where mushroom supplements live

Almost never used by mushroom supplements

Disease Claim

Tier 3 — prohibited

What it describes

Treating, preventing, or curing a named disease

Evidence bar

Full drug approval: controlled trials for safety and efficacy

FDA review before marketing

Yes — via the FDA drug approval process, not supplement law

Example claim

"Treats cancer" / "prevents Alzheimer’s"

Where mushroom supplements live

Not allowed — makes the product an unapproved drug

The 30-day notification behind a Tier 1 claim tells the FDA the claim exists — it is not FDA approval or verification that the claim is accurate. That distinction is the whole game for mushroom supplement marketing.

Framework per FDA regulatory guidelines for dietary supplements (Bailey, Critical Reviews in Food Science and Nutrition, 2020) and the Dietary Supplement Health and Education Act of 1994.

What Mushroom Supplement Companies Can Legally Say

Within the structure/function claim tier, mushroom supplement companies have meaningful latitude. Here are the types of claims that fall within permissible territory:

• Immune support language: "Supports immune function," "promotes healthy immune response," "helps maintain immune system activity"
• Cognitive support language: "Supports brain health," "promotes mental clarity," "helps maintain focus and memory"
• Energy and adaptogenic language: "Supports energy levels," "helps the body adapt to everyday stress," "promotes physical performance"
• Antioxidant language: "Contains antioxidants that support cellular health," "helps protect cells from oxidative stress"
• Liver and metabolic language: "Supports liver health," "helps maintain healthy blood sugar levels already within the normal range"

All of these describe effects on normal body structure or function. They do not name a disease. They do not claim the product prevents, treats, or cures anything.

The 30-day notification process is less protective than it sounds. The company notifies the FDA that it plans to market a specific structure/function claim. The FDA may respond with a concern, but it doesn't approve the claim or verify its accuracy before the company starts using it. The notification creates a record that the claim exists; it doesn't represent FDA endorsement.^[1]

The Legal vs. Illegal Claim Table: Mushroom Supplements

The following table shows how the legal line runs for specific mushroom supplement claim types. The "Legal basis" column identifies which regulatory framework permits or prohibits the claim.

The column on the right describes disease claims. Every item in that column would require the mushroom supplement to be classified as a drug and approved through the FDA drug approval process. A supplement label making those claims is in regulatory violation.

What 14 Years of FDA Warning Letters Reveal

The pattern of what actually triggers FDA enforcement action provides a practical view of where the line gets crossed.

A 2016 analysis by Brody, published in Comprehensive Reviews in Food Science and Food Safety, examined FDA warning letters across 14 years of supplement labeling enforcement.^[2] The consistent finding: disease claims were the single most common category of violation driving FDA warning letters. Companies that crossed from structure/function language into disease-specific language received warning letters at higher rates than companies making other types of labeling errors.

Real examples from FDA enforcement against mushroom supplement companies illustrate what disease claim language looks like in practice:

A turkey tail mushroom product labeled with language including "anti-cancer, antiviral, antibacterial" received enforcement attention. These terms claim the product acts against disease-causing agents and processes, which moves the claims from structure/function territory into disease claims requiring drug classification.

A maitake mushroom product marketed with language suggesting "cancer fighting properties" similarly received regulatory attention. "Cancer fighting" implies treatment or prevention of a disease, not support of normal body function.

A mushroom extract product marketed as an "adjunct therapy for cancer treatment" is explicitly framing the supplement as part of disease treatment, which is a disease claim that supplements cannot make.

In each case, the specific language used implied the product could affect a disease outcome rather than support normal healthy function. The Brody 2016 analysis shows this pattern across the full industry: companies frequently use the word "supports" in one part of their label while using disease-specific language elsewhere, creating mixed signals that fall into violation territory.^[2]

Why "Supports" Alone Doesn't Make a Claim Legal

One nuance that the warning letter data reveals: the legal status of a claim isn't determined only by the words on the label itself. Context shapes whether a structure/function claim remains legal or becomes an implied disease claim.

The FDA has consistently found that otherwise-legal structure/function language can be converted into illegal disease claims by surrounding context: testimonials mentioning specific diseases, imagery showing sick patients recovering, or website content describing the product as effective against a named condition. A label saying "supports immune function" is legal. The same product's website featuring testimonials from cancer patients describing their experiences with the supplement, combined with that label claim, creates an implied disease claim.

This is why the Brody 2016 analysis found warning letters citing not just label language but the full marketing context: website content, social media posts, and promotional materials all factor into whether the company is making a disease claim in practice, even if the label text alone might be technically compliant.

For a detailed breakdown of how context converts legal structure/function claims into illegal disease claims, and how the line specifically runs between the two, see Structure/Function Claims vs. Disease Claims: The Legal Line.

Why the Disclaimer Doesn't Guarantee Consumer Protection

The mandatory FDA disclaimer ("These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.") appears on virtually every mushroom supplement label. Its presence signals structure/function claim territory. Its existence should not be read as protection from inaccurate or unsubstantiated claims.

A 2022 study published in JAMA by Cohen and colleagues tracked what happened to 31 dietary supplement products after they received FDA warning letters for containing FDA-prohibited ingredients.^[3] Only 1 of the 31 (3%) was formally recalled by its manufacturer. When the researchers searched years later, most products were no longer for sale, but nearly a third (29%) remained available, and the majority of those still contained the prohibited ingredient that had triggered the warning letter. The warning letter process is oriented toward voluntary compliance: companies that receive letters can delay, contest, or in some cases keep selling products while regulatory correspondence proceeds, and a letter rarely forces a formal recall.

Cohen et al. (2022) · JAMA

Population

31 dietary supplements that received FDA warning letters for containing FDA-prohibited ingredients

Intervention

FDA warning letter issued to the manufacturer

Comparator

Product availability and content re-checked years later

Finding

Only 1 of 31 products (3%) was formally recalled. Most were no longer for sale years later, but 9 of 31 (29%) remained available — and most of those still contained the prohibited ingredient that triggered the letter.

narrow-scope Studied drug-adulterated supplements, not disease-claim labeling — but it directly measures how weakly a warning letter forces a product off the market.

Cohen et al., JAMA, 2022

A 2023 review by Li and colleagues, published in Innovations in Pharmacy, identified adverse event underreporting and weak enforcement as systematic gaps in FDA's dietary supplement oversight, describing the agency's regulatory approach under DSHEA as perfunctory in its practical effect on consumer protection.^[4]

Fact Check

Does the disclaimer mean the FDA vouches for the claim?

The claim

“A structure/function claim like 'supports immune function' means the benefit has been proven and cleared by the FDA.”

Common reading of the mandatory label disclaimer

What research shows

Misleading

The 30-day notification tells the FDA a claim exists; it is not review, approval, or verification that the claim is accurate. Under DSHEA, supplements are not required to prove efficacy before sale.

The claim may rest on strong human trials — or on in-vitro data extrapolated far beyond what it shows. The disclaimer signals what the product has NOT been through, not what it has.

Bailey, Critical Reviews in Food Science and Nutrition, 2020; Starr, American Journal of Public Health, 2015

These findings mean that mushroom supplement products making claims that cross the legal line can and do remain on sale after regulatory action. The disclaimer at the bottom of a label does not indicate the label's other claims have been reviewed for accuracy or that the product has been tested for efficacy.

The Structural Argument About DSHEA's Design

The regulation allowing structure/function claims with a 30-day notification requirement, and prohibiting disease claims without drug approval, was established in the Dietary Supplement Health and Education Act of 1994. DSHEA's post-market enforcement model has been consistently critiqued in academic literature.

A 2015 analysis by Starr, published in the American Journal of Public Health, characterized DSHEA's model as giving the FDA insufficient authority to protect consumers from deceptively marketed supplements.^[5] The core problem is burden of proof: under DSHEA, supplements don't need to prove efficacy before sale. The FDA must identify a violation and pursue enforcement after the fact. Millions of consumers can encounter claims before any enforcement action occurs, and the JAMA 2022 data shows that even after a warning letter is issued, formal recalls are rare and cited products can remain on sale.

The structure/function claim tier exists in part because of the political compromise that produced DSHEA: the supplement industry wanted the ability to make meaningful statements about their products' health benefits without the cost and timeline of drug approval. The result was a tier with a low evidentiary bar and no FDA pre-review, supervised primarily by a post-market enforcement system that the Starr 2015 and Li 2023 analyses identify as inadequate for consistent consumer protection.

What Consumers Can Take From the Claims Framework

The regulatory architecture has practical implications for anyone evaluating mushroom supplement marketing.

A structure/function claim ("supports immune function") tells you the company notified the FDA this claim exists and has some scientific substantiation on file. It doesn't tell you the claim is accurate, that the product was tested in humans, or that the FDA reviewed the substantiation. The claim may be backed by strong clinical research, or it may be backed by in-vitro laboratory data that extrapolates far beyond what it demonstrates.

A claim suggesting the supplement treats, prevents, or cures a specific disease is either illegal (if the product is a supplement) or indicates the product has been through FDA drug approval (which mushroom supplements have not). Disease-suggestive language in mushroom supplement advertising is a regulatory violation, but the enforcement record shows this doesn't mean the product disappears from the market quickly.

The disclaimer at the bottom is the system telling consumers what the claims haven't been through, not what they have. Reading it that way, as a signal of what's absent rather than what's present, is more accurate than reading it as a routine legal formality.

For practical guidance on evaluating mushroom supplement labels with this framework in mind, see What to Look for on a Mushroom Supplement Label. For how mushroom supplement companies approach staying compliant, see How Mushroom Companies Navigate FDA and FTC Restrictions.

For context on the FDA enforcement counterpart to the FTC actions discussed in this cluster, see FDA Warning Letters to Mushroom Companies: What Gets Flagged and FDA and Mushroom Supplements: How DSHEA Shapes What Companies Can (and Can't) Say.

The Bottom Line

FDA law divides supplement health claims into three tiers: structure/function claims (what most mushroom supplement labels use), authorized health claims (requiring FDA agreement on significant scientific evidence), and disease claims (prohibited without drug approval). The mandatory disclaimer at the bottom of mushroom supplement labels is a regulatory signal, not optional branding. A 14-year analysis of FDA warning letters found disease claims are the most consistent labeling violation, and a 2022 JAMA study found that only 3% of supplements cited in warning letters were formally recalled, meaning problematic products can stay on sale long after enforcement action begins. Consumers should read structure/function claims as representing the lowest regulatory bar for supplement health language, not as FDA endorsement of accuracy.

Frequently Asked Questions

Can mushroom supplements claim to boost immunity?

Mushroom supplements can claim to "support immune function" or "promote healthy immune response" under the structure/function claim tier of FDA law. These phrases describe effects on normal body function without implying disease treatment or prevention. What supplements cannot claim is immunity against infection or disease, prevention of specific immune disorders, or treatment of immunodeficiency conditions. The difference between "supports immune function" (legal) and "boosts immunity against cancer" (illegal disease claim) is the reference to a specific disease outcome.

What health claims are allowed on dietary supplements?

Dietary supplements can legally make structure/function claims that describe how ingredients affect normal body structure or function. Examples include "supports cognitive health," "maintains energy levels," and "promotes liver function." These require a 30-day FDA notification before marketing and a mandatory disclaimer. Supplements can also make authorized health claims if the FDA has reviewed and authorized the specific relationship between an ingredient and a health condition, which is uncommon. Disease claims (that a supplement treats, prevents, or cures a disease) are prohibited without drug approval.

Why do mushroom supplements say 'not intended to diagnose treat cure or prevent'?

That specific disclaimer language is required by federal regulation for any dietary supplement making structure/function claims. It is not optional brand language chosen by the company. Its presence signals that the label's health claims are structure/function claims, the lowest-evidence tier in the FDA framework. It also signals that those claims have not been reviewed by the FDA for accuracy. The disclaimer is the regulatory system telling consumers what the product has not been through: pre-market efficacy testing and FDA review.

What is a structure function claim on a supplement label?

A structure/function claim describes how a nutrient or ingredient affects normal body structure or function, without referencing a disease. "Supports immune function" is a structure/function claim. "Treats infection" is a disease claim. Companies can make structure/function claims on supplement labels by notifying the FDA within 30 days of first marketing the claim and including the mandatory disclaimer. The FDA does not pre-approve these claims; it reviews them after marketing if a complaint or inspection identifies a concern.

Can supplement companies say their product fights cancer?

No. "Fights cancer" is a disease claim that implies the supplement treats or prevents cancer. Dietary supplements cannot make disease claims without being classified as drugs and going through FDA drug approval, which requires controlled clinical trials demonstrating safety and efficacy for the specific disease claim. A mushroom supplement company making cancer-fighting claims on its label or in advertising is in regulatory violation. FDA warning letter data shows this is one of the most consistently cited violations in supplement enforcement history.

Sources & References

1. 1RTHM-01165·Bailey, Regan L (2020). “Current regulatory guidelines and resources to support research of dietary supplements in the United States..” Critical reviews in food science and nutrition.Study breakdown →PubMed →↩
2. 2RTHM-00765·Brody, Tom (2016). “Food and Dietary Supplement Package Labeling-Guidance from FDA's Warning Letters and Title 21 of the Code of Federal Regulations..” Comprehensive reviews in food science and food safety.Study breakdown →PubMed →↩
3. 3RTHM-01498·Cohen, Pieter A et al. (2022). “Recalls, Availability, and Content of Dietary Supplements Following FDA Warning Letters..” JAMA.Study breakdown →PubMed →↩
4. 4RTHM-01729·Li, WeiQi et al. (2023). “Narrative Review: The FDA's Perfunctory Approach of Dietary Supplement Regulations Giving Rise to Copious Reports of Adverse Events..” Innovations in pharmacy.Study breakdown →PubMed →↩
5. 5RTHM-00735·Starr, Ranjani R (2015). “Too little, too late: ineffective regulation of dietary supplements in the United States..” American journal of public health.Study breakdown →PubMed →↩